81.9%
Sensitivity
Multi-Cancer Early Detection
Genomic Testing for Early Cancer Screening
Multi-Cancer Early Detection
A novel methylation-based technology for early risk detection of eight high-incidence cancers from a single tube of blood.
- Proprietary patented methylation technology (Patent No. ZL202010774753.3, recipient of the 24th China Patent Excellence Award).
- Only one tube of blood required (10 mL blood sample).
- Covers eight high-incidence cancers, representing nearly 80% of the cancer population.
- 155,000 DNA methylation sites across 2,658 genes closely associated with cancer initiation and progression.
- Accurately identifies the tissue of origin, guiding further clinical examination and supporting earlier cancer detection and intervention.
99%
Specificity
94.5%
TOP2 tissue-of-origin accuracy
Comprehensive
One test covers screening & early warning for eight major high-incidence tumors.
Convenient
Non-invasive liquid biopsy via blood sampling, safe and easy to perform.
Early Detection
Identifies tumor signals ahead of imaging examinations.
Highly Accurate
Delivers superior analytical performance.
Real-time Monitoring
Enables effective evaluation of current cancer status.